reference/28987132

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28987132

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	87
issn	1699-048X 1699-3055
issueIdentifier	1
pageRange	82-87
publicationName	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
startingPage	82
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a88402bd59acac574785b0fb6767bb34 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b89fd849d40ba2b90f6648342ce4e3aa http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_7d434d5ec31f045830153493273d197e
bibliographicCitation	Wang X, Ren J, Zhang J, Yan Y, Jiang N, Yu J, Di L, Song G, Che L, Jia J, Zhou X, Yang H, Lyerly HK. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). Clinical and Translational Oncology. 2015 Aug 13;18(1):82–7. doi: 10.1007/s12094-015-1339-2.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e90de1da80cec7bec9798cac2006d4fc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a660f7ba6a6252067de21c5fced7c509 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_396b8e4983a257ae32af688058292499 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_157fe0b772fd603bf1ddcc50fb2e71d2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_67b9653e538f30cb4876d5623f1d552c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bf0d19e96ba718c34ac1e47b3dc47012 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ada36d966e83164c3f3e30a8de1be048 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc62419f1146b128813904c7c71bb43c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e0616e4c7e9a13c2643c4d1079577ca9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b4cf303a06d0a5e8007eb3bb35db7edf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3b7168b429199d9864271d1198627c3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e2898a44a6322bb6e8f6f4da345d9099 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c0a17710fd06134bac3041cde01651c7
date	2015-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s12094-015-1339-2 https://pubmed.ncbi.nlm.nih.gov/26266766
isPartOf	https://portal.issn.org/resource/ISSN/1699-3055 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32427 https://portal.issn.org/resource/ISSN/1699-048X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
discusses	http://id.nlm.nih.gov/mesh/M0005485 http://id.nlm.nih.gov/mesh/M0024707 http://id.nlm.nih.gov/mesh/M0021343
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b0484fdd4c5fbc5b1cb12a28197674d5 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1d2c6279569a5e5473d9efe0530fd802 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11451 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID108157 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5453 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661

Total number of triples: 50.